Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although Merck is providing it to the NHS in England at a ...

Manually producing the TLF involves an interplay of biostatisticians, terminology coders, statistical programmers, and ...

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to ...

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s own blood is modified at the bedside, or allogeneic therapies, created with ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Abzena, a San Diego-based CDMO and CRO focused on bioconjugates and complex biologics, has welcomed Taylor Boyd as its new ...

Anderson is expecting 2025 to be a pivotal year for his turnaround plan – which revolves around the removal of management ...

The latest biotech to emerge from the Flagship Pioneering incubator – Lila Sciences – has emerged with $200 million in seed ...